Trastuzumab deruxtecanVRN-101099, T-DXd, DS-8201a, DS 8201

1826843-81-5

Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

145 kDa (average)

98.49% (SEC-HPLC)